Comparison 5. Atovaquone‐proguanil (AP) versus halofantrine.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Treatment failure on or by day 28	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2 Parasite clearance time (mean; h)	2	205	Mean Difference (IV, Fixed, 95% CI)	14.76 [10.41, 19.10]
3 Fever clearance time (mean; h)	2	205	Mean Difference (IV, Fixed, 95% CI)	‐1.70 [‐9.41, 6.02]
4 Adverse events	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 Abdominal pain	2	216	Risk Ratio (M‐H, Random, 95% CI)	0.81 [0.14, 4.68]
4.2 Chills/Rigors	1	168	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.11, 3.89]
4.3 Cough	1	168	Risk Ratio (M‐H, Random, 95% CI)	0.71 [0.34, 1.52]
4.4 Diarrhoea	2	216	Risk Ratio (M‐H, Random, 95% CI)	0.57 [0.23, 1.39]
4.5 Headache	2	216	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.17, 6.84]
4.6 Insomnia	2	216	Risk Ratio (M‐H, Random, 95% CI)	0.62 [0.15, 2.60]
4.7 Moderate or severe	1	168	Risk Ratio (M‐H, Random, 95% CI)	0.38 [0.15, 0.91]
4.8 Myalgia	1	168	Risk Ratio (M‐H, Random, 95% CI)	0.14 [0.01, 2.72]
4.9 Nausea	1	48	Risk Ratio (M‐H, Random, 95% CI)	2.76 [0.62, 12.33]
4.10 Palpitations	1	168	Risk Ratio (M‐H, Random, 95% CI)	0.5 [0.05, 5.41]
4.11 Pruritus	2	216	Risk Ratio (M‐H, Random, 95% CI)	1.20 [0.51, 2.87]
4.12 Vomiting	2	216	Risk Ratio (M‐H, Random, 95% CI)	3.47 [0.66, 18.43]
4.13 Weakness	1	168	Risk Ratio (M‐H, Random, 95% CI)	0.25 [0.03, 2.19]